ParinGenix Inc.

ParinGenix Inc. is developing a safer, nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity. This heparin derivative, 2-O, 3-O desulfated heparin, is the drug substance in ParinGenix's lead product, PGX-100.

ParinGenix has raised more than $25 million to develop PGX-100 in various clinical indications including COPD. Investors in ParinGenix, in addition to Research Corporation Technologies, have included CHL Medical Partners (Stamford, Conn.), Domain Associates LLC (Princeton, N.J.) and Aurora Funds (Durham, N.C.), joined RCT in the financing.

Inventor/Founder

Thomas Kennedy, M.D., Carolinas Medical Center

RCT Contact

Christopher P. Martin, Senior Vice President and CFO

Therapeutics and Biotechnology

Medical Devices